World Conference on Lung Cancer 2024
Experts at World Conference on Lung Cancer 2024 analyze critical lung cancer studies including HARMONi-02, SKIPPirr, and TROPION-Lung01, examining end points such as progression-free survival, overall survival across histologies, and the potential of novel treatments like amivantamab to advance therapeutic strategies for various patient subgroups.
EP. 1: Highlights from WCLC 2024: CheckMate -77T vs. CheckMate -816
September 19th 2024Panelists discuss how the latest outcomes from CheckMate-77T demonstrate improved efficacy of neoadjuvant immunotherapy in early-stage non–small cell lung cancer compared with CheckMate-816, potentially revolutionizing treatment strategies and enhancing long-term survival rates for patients with lung cancer.
EP. 2: WCLC 2024: Analyzing SKIPPirr Data Outcomes for Lung Cancer Advancements
September 19th 2024Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.
EP. 3: HARMONi-02 Reveals Key Lung Cancer Insights at WCLC 2024
September 19th 2024Panelists discuss how the HARMONi-02 trial presented at World Conference on Lung Cancer 2024 revealed key lung cancer insights, focusing on progression-free survival and immune-related response criteria end points, while emphasizing the trial’s significance for specific patient subgroups.
EP. 4: Exploring Outcomes From TROPION-Lung01 Presented at WCLC 2024
September 19th 2024Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on overall survival outcomes in patients with lung cancer, with a particular focus on survival rates across different histological subtypes.
